Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43234   clinical trials with a EudraCT protocol, of which   7153   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2018-000137-13
    Sponsor's Protocol Code Number:ORARIALS-01
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2018-10-09
    Trial results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2018-000137-13
    A.3Full title of the trial
    A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
    Ensayo en fase III aleatorizado y controlado con placebo de arimoclomol en esclerosis lateral amiotrófica
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to compare the use of Arimoclomol with placebo in patients with Amyotrophic Lateral Sclerosis
    Ensayo controlado con placebo de arimoclomol en esclerosis lateral amiotrófica
    A.4.1Sponsor's protocol code numberORARIALS-01
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT03491462
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorOrphazyme A/S
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportOrphazyme A/S
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationOrphazyme A/S
    B.5.2Functional name of contact pointSenior Clinical Project Manager
    B.5.3 Address:
    B.5.3.1Street AddressOle Maaløes Vej 3
    B.5.3.2Town/ cityCopenhagen N
    B.5.3.3Post codeDK-2200
    B.5.4Telephone number004553706909
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/06/406
    D.3 Description of the IMP
    D.3.1Product nameArimoclomol
    D.3.2Product code BRX-345
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNARIMOCLOMOL
    D.3.9.1CAS number 368860-21-3
    D.3.9.2Current sponsor codeBRX-345
    D.3.9.4EV Substance CodeSUB187159
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Amyotrophic Lateral Sclerosis
    Esclerosis lateral amiotrófica
    E.1.1.1Medical condition in easily understood language
    Amyotrophic Lateral Sclerosis
    Esclerosis lateral amiotrófica
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10002026
    E.1.2Term Amyotrophic lateral sclerosis
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine the efficacy of chronic treatment with arimoclomol 1200 mg/day (400 mg TID) compared to placebo over 76 weeks in subjects with ALS as assessed with Combined Assessment of Function and Survival (CAFS)
    Determinar la eficacia del tratamiento crónico con 1200 mg/día (400 mg TID) de arimoclomol en comparación con placebo durante 76 semanas en sujetos con ELA según la evaluación mediante CAFS (Evaluación combinada de función y supervivencia, Combined Assessment of Function and Survival)
    E.2.2Secondary objectives of the trial
    To evaluate the impact of arimoclomol 1200 mg/day (400 mg TID) compared to placebo on:
    • Time to permanent assisted ventilation (PAV)/tracheostomy free survival
    • Disease progression as measured by change from Baseline of the ALSFRS-R
    • Progression of respiratory dysfunction as measured by change from Baseline of the slow vital capacity (SVC)
    Evaluar el impacto del tratamiento con 1200 mg/día (400 mg TID) de arimoclomol en comparación con placebo respecto a lo siguiente:
    •Tiempo transcurrido hasta necesitar ventilación mecánica permanente (VMP)/supervivencia sin traqueotomía
    •Progresión de la enfermedad medida mediante el cambio en la ALSFRS-R respecto a la visita basal
    •Progresión de la alteración de la función respiratoria medida según el cambio respecto a la visita basal en la capacidad vital lenta (CVL)
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Capable of- and willing to- provide written informed consent and comply with trial procedures.
    2. Subject is male or female ≥18 years of age.
    3. Subject meets revised El Escorial criteria for clinically possible, clinically probable / clinically probable ALS laboratory-supported or clinically definite ALS, or familial ALS.
    4. 18 months or less since first appearance of weakness (e.g. limb weakness, dysarthria, dysphagia, shortness of breath).
    5. ALSFRS-R ≥35 and erect SVC % predicted ≥ 70% at Screening.
    6. Able and willing to travel to the site, and in the investigator’s opinion is likely to attend visits for at least 24 weeks.
    7. All sexually active female subjects of child-bearing potential (postmenarchal)* must agree not to intend to become pregnant and use a highly effective method of contraception** during the trial through 1 month after the last dose of trial medication. If the subject is a sexually active male with female partners of child-bearing potential (postmenarchal) he must use a condom with or without spermicide in addition to the birth control used by their partners during the trial until 3 months after the last dose of trial medication.
    8. Stable dose of riluzole (50 mg twice daily) for a minimum of 14 days prior to Day 1 (Baseline), or has not taken it for 14 days prior to Day 1.
    1. Capaz y dispuesto a dar su consentimiento informado por escrito y cumplir los procedimientos del ensayo.
    2. Los sujetos serán hombres o mujeres de al menos 18 años de edad.
    3. Los sujetos deben cumplir los criterios revisados de El Escorial de ELA clínicamente posible, ELA clínicamente probable/clínicamente probable respaldada por los valores analíticos, ELA clínicamente definida o ELA familiar.
    4. 18 meses o menos desde la primera aparición de debilidad (por ejemplo, debilidad en las extremidades, disartria, disfagia, dificultades respiratorias).
    5. ALSFRS-R ≥ 35 y pronóstico de % de VCL de pie ≥ 70 % en la selección.
    6. Capaz y dispuesto a desplazarse hasta el centro y, en opinión del investigador, es probable que acuda a las visitas durante al menos 24 semanas.
    7. Todas las mujeres sexualmente activas potencialmente fértiles (posmenarquia*) deben aceptar no intentar quedarse embarazadas y usar un método anticonceptivo de gran eficacia** durante el ensayo hasta 1 mes después de la administración de la última dosis de la medicación del ensayo. Si un sujeto es un varón sexualmente activo con parejas femeninas potencialmente fértiles (posmenarquia), debe usar preservativo con o sin espermicida además del método anticonceptivo que usen sus parejas durante el ensayo hasta 3 meses después de la administración de la última dosis del fármaco del ensayo.
    8. Dosis estable de riluzol (50 mg dos veces al día) durante al menos los 14 días anteriores al día 1 (visita basal) o no haberlo tomado durante los 14 días anteriores al día 1.
    E.4Principal exclusion criteria
    1. Tracheostomy or use of non-invasive ventilation for more than 2 hours during waking hours at the time of Screening and Baseline visits.
    2. Pregnant or breast-feeding.
    3. Current or anticipated use of diaphragmatic pacing during the trial.
    4. Exposure to any investigational treatment within 4 weeks or <5 half-lives of the Screening visit, whichever is longest and/or participated in any prior ALS clinical trial receiving active drug treatment (with the exception described in exclusion criterion 5).
    5. Previously or currently treated with edaravone. However, up to 18 subjects on stable (i.e. minimum 6 months’) treatment with edaravone and who otherwise fulfil the eligibility criteria are planned for enrolment (limited to countries where edaravone has a marketing authorisation for treatment of ALS).
    6. Any of the following medically significant conditions:
    a) Neurological impairment/dysfunction or unstable psychiatric illness that in the investigator’s opinion is likely to interfere with assessment of ALS disease progression.
    b) Clinically significant unstable medical condition other than ALS, which would present a risk to a subject to participate in the trial
    c) Presence of dementia that impairs the ability of the subject to provide informed consent according to the PI decision.
    d) Known or suspected allergy or intolerance to the IMP (arimoclomol or constituents);
    e) Chronic infection particularly HIV or Hepatitis B or C.
    f) Clinically significant renal or hepatic disease
    g) Aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase ≥3 times the upper limit of normal [ULN], bilirubin≥2 times the ULN, or creatinine ≥1.5 times the ULN). Laboratory tests may be repeated once at Screening. Reasons to repeat laboratory tests may include that the medication causing laboratory abnormality was suspended, any other suspected cause may no longer exist, or to rule out laboratory error.
    h) Cancer that is currently under active treatment or is likely to require treatment during the trial that may alter the subject´s function and thereby interfere with assessment of ALS disease progression.
    i) Any other condition that in the investigator’s opinion would present a risk to a subject to participate in the trial, interfere with the assessment of safety or has an increased risk of causing death during the trial.

    * Non child-bearing potential is defined as post-menopausal (minimum of 12 months with no menses and follicle-stimulating hormone in the post-menopausal range) or sterilisation (hysterectomy, oophorectomy, or bilateral tubal ligation).

    ** Highly effective methods of contraception include combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable); intrauterine device; intrauterine hormone-releasing system; bilateral tubal occlusion; and vasectomised partner.

    According to the recommendations from the Clinical Trial Facilitation Group (CTFG, 2014), sexual abstinence is considered a highly effective birth control method only if it is defined as refraining from heterosexual intercourse during the trial until 1 week after the last dose of trial medication (for female subjects of child-bearing potential) and for 3 months after the last dose of trial medication (for male subjects with female partners of child-bearing potential). The reliability of sexual abstinence needs to be evaluated by the investigator in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.
    1. Traqueotomía o uso de ventilación no invasiva durante más de 2 horas durante las horas de vigilia en el momento de las visitas de selección y basal.
    2. Embaraza o en período de lactancia.
    3. Usando en la actualidad, o previsión de que vaya a usar un marcapasos diafragmático durante el ensayo.
    4. Exposición a algún tratamiento en fase de investigación en las 4 semanas o < 5 semividas anteriores a la visita de selección, lo que sea más largo, y/o ha participado en algún ensayo clínico previo de ELA recibiendo tratamiento farmacológico activo (con la excepción descrita en el criterio de exclusión 5 .).
    5. Previamente o actualmente tratado con edaravona. Sin embargo, se prevé la inclusión en el ensayo de hasta 18 sujetos con tratamiento estable (es decir, durante al menos 6 meses) con edaravona y que cumplan todos los demás criterios de idoneidad (limitados a los países en los que la edaravona cuente con autorización de comercialización como tratamiento para la ELA).
    6. Alguno de las condiciones médicamente significativos que se indican a continuación:
    a)Deterioro/disfunción neurológica o enfermedad psiquiátrica inestable que, en opinión del investigador, probablemente interfiera en la valoración de la progresión de la ELA
    b)Enfermedad inestable clínicamente significativa que no sea ELA que supondría un riesgo en caso de que el sujeto participara en el ensayo
    c)Presencia de demencia que afecte a la capacidad del sujeto para dar su consentimiento informado, de acuerdo con la decisión del IP
    d)Alergia o intolerancia conocida o sospechada al PEI (arimoclomol o sus componentes)
    e)Infección crónica, especialmente por el VIH o por el virus de la hepatitis B o C.
    f)Nefropatía o hepatopatía clínicamente significativa
    g)Valores de aspartato aminotransferasa, alanina aminotransferasa y lactato deshidrogenasa ≥ 3 veces el límite superior de la normalidad (LSN), bilirrubina ≥ 2 veces el LSN o creatinina ≥ 1,5 veces el LSN. Las pruebas analíticas podrán repetirse una vez en durante la selección. Los motivos para repetir las pruebas analíticas pueden incluir el hecho de que se haya suspendido el medicamento que provocaba la alteración analítica, que ya no exista ninguna otra causa de la que se sospechaba o para descartar un error de laboratorio.
    h)Cáncer que se encuentre en ese momento en tratamiento activo o que es probable que necesite tratamiento durante el ensayo que pueda alterar la función del sujeto y, por consiguiente, interferir en la evaluación de la progresión de la ELA.
    i)Cualquier otro trastorno que, en opinión del investigador, supondría un riesgo para el sujeto en caso de que participara en el ensayo, interferiría en la evaluación de la seguridad o tendría un mayor riesgo de provocar la muerte durante el ensayo.

    * Se define «no fértiles» como el estado posmenopáusico (al menos 12 meses sin menstruación y hormona foliculoestimulante en el intervalo posmenopáusico) o la esterilización (histerectomía, ovariectomía o ligadura bilateral de trompas).

    ** Los métodos anticonceptivos de gran eficacia incluyen la anticoncepción hormonal combinada (que contiene estrógenos y progestágenos) asociada con la inhibición de la ovulación (por vía oral, intravaginal o transdérmica), los anticonceptivos hormonales solo con progestágeno asociados con la inhibición de la ovulación (por vía oral, inyectable o implantable), el dispositivo intrauterino, el sistema de liberación hormonal intrauterino, la oclusión bilateral de las trompas y la vasectomía de la pareja.

    Conforme a las recomendaciones del Grupo de Facilitación de Ensayos Clínicos (CTFG, 2014), la abstinencia sexual se considera un método anticonceptivo de gran eficacia únicamente si se define como abstinencia de relaciones sexuales heterosexuales durante el ensayo hasta 1 semana después de la administración de la última dosis de la medicación del ensayo (para mujeres potencialmente fértiles) y durante los 3 meses siguientes a la administración de la última dosis de la medicación del ensayo (para varones con parejas potencialmente fértiles). El investigador debe evaluar la fiabilidad de la abstinencia sexual en relación con la duración del ensayo clínico y el estilo de vida preferido y habitual del sujeto.
    E.5 End points
    E.5.1Primary end point(s)
    Combined assessment of function and survival (CAFS) over a treatment period of 76 weeks (or end-of-trial)
    Evaluación combinada de función y supervivencia (CAFS) durante un período de tratamiento de 76 semanas (o fin del ensayo)
    E.5.1.1Timepoint(s) of evaluation of this end point
    76 weeks (or end-of-trial)
    76 semanas (o fin del ensayo)
    E.5.2Secondary end point(s)
    • Time to PAV/tracheostomy/death
    • Change from Baseline to Week 76 (or end-of-trial) in ALSFRS-R
    • Change from Baseline to Week 76 (or end-of-trial) in SVC
    •Tiempo transcurrido hasta la VMP/traqueotomía/muerte
    •Cambio en la ALSFRS-R desde la visita basal hasta la semana 76 (o fin del ensayo)
    •Cambio en la CVL desde la visita basal hasta la semana 76 (o fin del ensayo)
    E.5.2.1Timepoint(s) of evaluation of this end point
    76 weeks (or end-of-trial)
    76 semanas (o fin del ensayo)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA15
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months7
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 160
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 71
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state16
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 132
    F.4.2.2In the whole clinical trial 231
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Subjects who complete 76 weeks of randomised treatment will be offered participation in a separate open-label extension trial through means of a separate clinical trial protocol.
    A los sujetos que completen 76 semanas de tratamiento aleatorizado se les ofrecerá la participación en un ensayo de extensión de etiqueta abierta a través de un protocolo de ensayo clínico por separado
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-10-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-10-08
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands